Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approves once-weekly dosing option for Kyprolis in relapsed or refractory multiple myeloma

Oct. 2, 2018

CHIT1 unveiled as a novel therapeutic target in IPF

Oct. 2, 2018

Patient recruitment ongoing in phase II study of PRCL-02 in chronic plaque psoriasis

Oct. 2, 2018

Kigabeq granted European marketing authorization

Oct. 2, 2018

Yervoy, Opdivo go to Stockholm: 2018 Medicine Nobel honors checkpoint inhibitor work

Oct. 2, 2018

Ocugen initiates the first trial in its phase III program of OCU-310 in dry eye disease

Oct. 2, 2018

Salk awarded CIRM grant to support development of immune-tolerant human islet-like organoids

Oct. 2, 2018

Mylan initiates phase III comparative study of MYL-1701P and Eylea

Oct. 2, 2018

Phase I study of Butantan Institute's H7N9 influenza antigen

Oct. 2, 2018

Patient recruitment is ongoing in phase II study of BI-730357 in plaque psoriasis

Oct. 2, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...